Fiera Capital Corp Sells 46,721 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Fiera Capital Corp cut its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 3.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,354,469 shares of the company’s stock after selling 46,721 shares during the period. Fiera Capital Corp’s holdings in Apellis Pharmaceuticals were worth $39,063,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in APLS. HighVista Strategies LLC lifted its holdings in shares of Apellis Pharmaceuticals by 4.1% in the 2nd quarter. HighVista Strategies LLC now owns 7,566 shares of the company’s stock worth $290,000 after buying an additional 300 shares during the period. Amalgamated Bank lifted its stake in Apellis Pharmaceuticals by 5.4% in the second quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock worth $268,000 after acquiring an additional 359 shares during the period. Simplicity Wealth LLC grew its holdings in Apellis Pharmaceuticals by 0.6% during the 2nd quarter. Simplicity Wealth LLC now owns 78,746 shares of the company’s stock worth $3,021,000 after acquiring an additional 499 shares in the last quarter. Oppenheimer Asset Management Inc. increased its position in Apellis Pharmaceuticals by 8.3% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 8,694 shares of the company’s stock valued at $511,000 after purchasing an additional 664 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Apellis Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after purchasing an additional 781 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

Insider Buying and Selling at Apellis Pharmaceuticals

In other news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at $3,623,000. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.80% of the stock is currently owned by corporate insiders.

Apellis Pharmaceuticals Trading Up 4.3 %

Shares of Apellis Pharmaceuticals stock opened at $29.98 on Friday. The stock has a market cap of $3.65 billion, a PE ratio of -10.94 and a beta of 0.87. The firm has a fifty day moving average price of $31.02 and a 200 day moving average price of $37.02. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $73.80. The company has a debt-to-equity ratio of 1.73, a current ratio of 5.08 and a quick ratio of 4.18.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The company had revenue of $196.83 million for the quarter, compared to analysts’ expectations of $200.00 million. During the same quarter in the previous year, the business posted ($1.17) EPS. The business’s quarterly revenue was up 78.3% on a year-over-year basis. Equities research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.4 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on APLS. JPMorgan Chase & Co. cut their price objective on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating on the stock in a report on Friday, September 13th. William Blair initiated coverage on Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They set an “outperform” rating for the company. Needham & Company LLC cut their target price on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday. The Goldman Sachs Group decreased their price target on shares of Apellis Pharmaceuticals from $71.00 to $36.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Citigroup lowered their target price on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a research note on Wednesday. Six equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $51.06.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).